Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Greenberg

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|March 5, 2015
Myelodysplastic syndromes, version 2.2015Peter L Greenberg, Richard M Stone, Rafael Bejar, et al.
Leukemia Research|September 17, 2018
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDSYasushi Miyazaki, Heinz Tuechler, Guillermo Sanz, et al.
Blood|June 24, 2016
Time-dependent changes in mortality and transformation risk in MDSMichael Pfeilstöcker, Heinz Tuechler, Guillermo Sanz, et al.
Blood|June 29, 2012
Revised international prognostic scoring system for myelodysplastic syndromesPeter L Greenberg, Heinz Tuechler, Julie Schanz, et al.
Blood|August 19, 2016
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromesPeter L Greenberg, Heinz Tuechler, Julie Schanz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2025
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025Peter L Greenberg, Richard M Stone, Yasmin Abaza, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022Peter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Blood|April 30, 2020
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDSLuca Malcovati, Kristen Stevenson, Elli Papaemmanuil, et al.
Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Journal of the National Comprehensive Cancer Network : JNCCN|March 5, 2015
Myelodysplastic syndromes, version 2.2015Peter L Greenberg, Richard M Stone, Rafael Bejar, et al.
Leukemia Research|September 17, 2018
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDSYasushi Miyazaki, Heinz Tuechler, Guillermo Sanz, et al.
Blood|June 24, 2016
Time-dependent changes in mortality and transformation risk in MDSMichael Pfeilstöcker, Heinz Tuechler, Guillermo Sanz, et al.
Blood|June 29, 2012
Revised international prognostic scoring system for myelodysplastic syndromesPeter L Greenberg, Heinz Tuechler, Julie Schanz, et al.
Blood|August 19, 2016
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromesPeter L Greenberg, Heinz Tuechler, Julie Schanz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2025
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025Peter L Greenberg, Richard M Stone, Yasmin Abaza, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022Peter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Blood|April 30, 2020
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDSLuca Malcovati, Kristen Stevenson, Elli Papaemmanuil, et al.
Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.
Pageof 10